Kaitlin M. Kestenberg-Messina - Apr 1, 2024 Form 3 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
COO and SVP, Compliance
Signature
/s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as attorney-in-fact
Stock symbol
ADMA
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
3
Date filed
4/2/2024, 09:00 PM
Previous filing
Apr 2, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ADMA Common Stock 114K Apr 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADMA Restricted Stock Units Apr 1, 2024 Common Stock 5K $0.00 Direct F2
holding ADMA Restricted Stock Units Apr 1, 2024 Common Stock 25K $0.00 Direct F3
holding ADMA Restricted Stock Units Apr 1, 2024 Common Stock 20K $0.00 Direct F4
holding ADMA Restricted Stock Units Apr 1, 2024 Common Stock 71.3K $0.00 Direct F5
holding ADMA Restricted Stock Units Apr 1, 2024 Common Stock 30K $0.00 Direct F6
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 5K $10.80 Direct F7
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 2.5K $8.98 Direct F8
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 5K $5.00 Direct F9
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 5K $4.72 Direct F10
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 6.65K $5.94 Direct F11
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 1.56K $4.31 Direct F12
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 937 $4.31 Direct F13
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 20.9K $2.59 Direct F14
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 13.3K $2.83 Direct F15
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 30K $2.35 Direct F16
holding ADMA Stock Option (Right to Buy) Apr 1, 2024 Common Stock 10K $1.55 Direct F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 114,275 shares acquired pursuant to the vesting of restricted stock units ("RSUs").
F2 On February 25, 2021, the Company granted the reporting person 20,000 RSUs, 5,000 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
F3 On September 28, 2021, the Company granted the reporting person 100,000 RSUs, 25,000 of which are currently unvested, with 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
F4 On March 7, 2022, the Company granted the reporting person 40,000 RSUs, 20,000 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
F5 On March 6, 2023, the Company granted the reporting person 95,000 RSUs, 71,250 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
F6 On July 24, 2023, the Company granted the reporting person 30,000 RSUs, all of which remain unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
F7 The incentive stock options were granted to the reporting person on January 30, 2015, which are fully vested in accordance with the Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (the "Plan").
F8 The incentive stock options were granted to the reporting person on July 30, 2015, which are fully vested in accordance with the Plan.
F9 The incentive stock options were granted to the reporting person on February 14, 2017, which are fully vested in accordance with the Plan.
F10 The incentive stock options were granted to the reporting person on May 3, 2018, which are fully vested in accordance with the Plan.
F11 The incentive stock options were granted to the reporting person on October 9, 2018, which are fully vested in accordance with the Plan.
F12 The incentive stock options were granted to the reporting person on June 5, 2019, which are fully vested in accordance with the Plan.
F13 The non-qualified stock options were granted to the reporting person on June 5, 2019, which are fully vested in accordance with the Plan.
F14 The incentive stock options were granted to the reporting person on March 10, 2020, which are fully vested in accordance with the Plan.
F15 The incentive stock options were granted to the reporting person on August 19, 2020, 2,084 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date.
F16 The incentive stock options were granted to the reporting person on February 25, 2021, 6,875 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date.
F17 The incentive stock options were granted to the reporting person on July 19, 2021, 3,334 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney